10:21 AM EDT, 05/01/2025 (MT Newswires) -- Amicus Therapeutics ( FOLD ) shares were down 11% in recent trading on Thursday after the company announced its Q1 results.

The company reported Q1 non-GAAP earnings of $0.03 per diluted share, compared with a loss of $0.02 a year earlier.

Analysts polled by FactSet expected EPS of $0.08.

Net product revenue for the quarter ended March 31 was $125.2 million, up from $110.4 million a year earlier. Analysts expected $135.9 million.

The company reduced its projection for 2025 revenue growth to a range of 15% to 22% from the previously provided range of 17% to 24%.

Price: 6.88, Change: -0.81, Percent Change: -10.48